Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide : A Study on Behalf of GETH-TC
Fonseca-Santos, Marta (Hospital Universitario de Salamanca)
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón)
López-Godino, Oriana (Hospital General Universitario Morales Meseguer (Múrcia))
Herruzo-Delgado, Beatriz (Hospital Regional Universitario de Málaga)
Bermudez, Maria Aranzazu (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
García Cadenas, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Huguet, María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ferra-Coll, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Esquirol, Albert (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Cortés-Rodriguez, María (Universidad de Salamanca)
Yáñez, Lucrecia (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Pascual Cascón, María Jesús (Hospital Regional Universitario (Màlaga, Andalusia))
Heras, Inmaculada (Hospital General Universitario Morales Meseguer (Múrcia))
Kwon, Mi (Hospital General Universitario Gregorio Marañón)
López Corral, Lucia (Hospital Universitario de Salamanca)

Date:	2024
Abstract:	Background. Chronic graft-versus-host disease (cGVHD) is a cause of late morbidity and nonrelapse mortality (NRM) after allogenic hematopoietic stem cell transplantation (allo-HSCT). Although studies evaluating haploidentical allo-HSCT (haplo-HSCT) using posttransplant cyclophosphamide (PTCy) demonstrate lower cGVHD rates, comprehensive data describing the clinical profile, risk factors, or outcomes of cGVHD within this platform are scarce. Methods. We conducted a retrospective multicenter analysis of 389 consecutive patients who underwent haplo-HSCT PTCy in 7 transplant centers of the Spanish Group Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC) between 2008 and 2020 describing incidence, clinical profile, risk factors, and cGVHD outcomes. Results. Ninety-five patients of 389 developed cGVHD. Our data revealed that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis and that the strongest predictor for cGVHD was previous acute GVHD (P = 0. 031). Also, recipient age ≥60 y (P = 0. 044) was protective against cGVHD. Moreover, patients with moderate cGVHD had longer event-free survival at 3 y than other patients (P = 0. 016) and a lower relapse rate at 3 y (P = 0. 036). Conclusions. Our results support the fact that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis. In this series, patients who develop moderate cGVHD after haplo-HSCT PTCy had a higher overall survival and event-free survival, and lower relapse, suggesting higher graft-versus-leukemia effect. Although this is the largest series focused on characterizing cGVHD in haplo-HSCT PTCy, further prospective studies are needed to confirm the findings.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Transplantation, Vol. 108 Núm. 10 (October 2024) , p. 2134-2143, ISSN 1534-6080

DOI: 10.1097/TP.0000000000005034

10 p, 894.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles